EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.

Tandem is a medical device company located in San Diego. The company manufactures and sells an automated drug delivery system primarily for use in home-administered IV's. The device is a relatively simple mechanical pump that is simpler and safer to use than standard IV therapy.

Next Breath, LLC is a contract pharmaceutical research and development organization dedicated to pre-clinical identification and evaluation of commercially viable respiratory and nasal drug delivery platforms. NB's business will discover and exploit optimal drug and delivery device combinations that will increase the company's partners' probability of success when their products advance into human clinical trials and the marketplace. Next Breath seeks to meet the pharmaceutical industry's outsourcing needs and to provide intellectual expertise to biotechnology companies that are developing inhalation products.

Therataxis LLC models brain transport processes and designs delivery methods for therapies. The simulation and prediction of transport mechanisms, and their direct delivery devices, provide the necessary link in developing successful therapies of the brain by ensuring proper delivery. Their currently marketed products are surgical simulation software and simulation-based device designs.

Vapore is the developer of MyPurMist, a device that provides soothing hot steam on demand. The directed humidification (vapor) of MyPurMist brings warmth into the sinuses which thins mucus and makes breathing easier. The moisture in the mist helps to relieve symptoms by soothing irritated tissues in the nose and throat, calming coughs and reducing dryness.

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.